LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Corcept Therapeutics Inc

Chiusa

SettoreSettore sanitario

71.26 2.5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

68.52

Massimo

71.47

Metriche Chiave

By Trading Economics

Entrata

15M

35M

Vendite

37M

194M

P/E

Media del settore

63.598

35.664

EPS

0.169

Margine di Profitto

18.078

Dipendenti

500

EBITDA

23M

27M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+94.52% upside

Dividendi

By Dow Jones

Utili prossimi

29 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

173M

7.5B

Apertura precedente

68.76

Chiusura precedente

71.26

Notizie sul Sentiment di mercato

By Acuity

57%

43%

336 / 371 Classifica in Healthcare

Corcept Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 set 2025, 17:03 UTC

I principali Market Mover

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 set 2025, 16:49 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 set 2025, 16:11 UTC

I principali Market Mover

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 set 2025, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline as Yen Strengthens -- Market Talk

16 set 2025, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 set 2025, 23:20 UTC

Discorsi di Mercato

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 set 2025, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 set 2025, 20:51 UTC

Discorsi di Mercato

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 20:25 UTC

Utili

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 set 2025, 20:24 UTC

Utili

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 set 2025, 19:19 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 set 2025, 18:52 UTC

Discorsi di Mercato

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 set 2025, 18:40 UTC

Acquisizioni, Fusioni, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 set 2025, 18:38 UTC

Discorsi di Mercato

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 set 2025, 18:19 UTC

Discorsi di Mercato

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 set 2025, 18:01 UTC

Discorsi di Mercato

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 set 2025, 17:34 UTC

Discorsi di Mercato

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 set 2025, 16:53 UTC

Utili

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 set 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 16:15 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Commodities Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Energy Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 set 2025, 15:22 UTC

Discorsi di Mercato

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 set 2025, 15:21 UTC

Discorsi di Mercato

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Confronto tra pari

Modifica del prezzo

Corcept Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

94.52% in crescita

Previsioni per 12 mesi

Media 135.25 USD  94.52%

Alto 145 USD

Basso 121 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Corcept Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

336 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat